COVID-19 deaths cross 2 million mark in the European region – WHO
The World Health Organization on May 12 said COVID-19 deaths have exceeded the 2 million mark for countries in the WHO European Region.
New Search
If you are not happy with the results below please do another search
Search
50 search results for:
Biden marks 1 million Americans dead from COVID
/in Congress, Coronavirus Disease (COVID-19) Pandemic, Coronavirus Disease 2019 (COVID-19), Coronavirus Disease 2019 (COVID-19), Coronavirus Infections, Coronavirus Mutations, Coronavirus Restrictions, Coronavirus surge, COVID-19 booster shots, COVID-19 Deaths, COVID-19 Infections, COVID-19 shots, COVID-19 Therapeutic, COVID-19 therapeutic candidates, COVID-19 Therapeutics, COVID-19 Therapies, COVID-19 treatment pill, COVID-19 vaccination rates, Covid-19 Variants, Joe Biden, Pandemics, Reuters Tally, SARS-CoV-2 virus, Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2), Summits, United States, White House, White House coronavirus task forcePresident Joe Biden on May 12 commemorated the death of 1 million people in the United States from COVID-19, marking what he called “a tragic milestone” and urging Americans to “remain vigilant” amid the ongoing pandemic.
North Korea reports first COVID outbreak, orders lockdown in “gravest emergency”
/in Coronavirus, COVAX Facility, COVID-19 Infections, COVID-19 Lockdown Measures, COVID-19 vaccination rates, COVID-19 Vaccinations, North Korea, Omicron (B.1.1.529) (South Africa), Outbreaks, Pyongyang, South Korea, World Health OrganizationNorth Korea reported the country’s first COVID-19 outbreak on May 12, calling it the “gravest national emergency” and ordering a national lockdown, with state media saying an Omicron variant had been detected in the capital, Pyongyang.
Moderna completes FDA submission for use of COVID shot in adolescents, kids
/in Adolescents, Children, COVID-19 shots, FDA, Moderna, mRNA-1273/Moderna COVID-19 Vaccine (Moderna)Moderna Inc. has made all necessary submissions required by the U.S. Food and Drug Administration for emergency use authorization of the company’s COVID-19 vaccine in adolescents and children.
Arkansas sues drugmakers, pharmacy benefit managers over insulin costs
/in Arkansas, Blockbusters, Cigna, CVS Health, Eli Lilly, Express Scripts Holding, Insulin, Lawsuits, Novo Nordisk, OptumRx, Pharmacy Benefit Managers, Prescription Drug Costs, Retail Pharmacies, Sanofi, Therapeutics, UnitedHealth GroupThe Arkansas attorney general on May 11 accused drugmakers and pharmacy benefit managers of colluding to drive up the price of insulin drugs, the latest in a series of lawsuits to take aim at skyrocketing costs for the life-sustaining medicine.
Inovio Taps New CEO, Drops COVID-19 Vaccine Candidate
/in Appointments, Business, Clinical Trials, COVID-19 Vaccines, Immune Response, Inovio Pharmaceuticals, People on the Move, Promotions, R&D, Resignations, T-CellsInovio Pharmaceuticals announced a leadership change at the helm and the discontinuation of a Phase III COVID-19 vaccine study.
Congressional Report Claims Emergent Mishap Destroyed 400 Million Doses of J&J Vaccine
/in AstraZeneca, Business, Coronavirus Disease (COVID-19) Pandemic, COVID-19 Doses, Emergent BioSolutions, House of Representatives, Janssen COVID-19 Vaccine (J&J), Johnson & Johnson, Manufacturing, U.S. governmentJust as Emergent BioSolutions looked to be making some headway in course corrections following a production mishap that ruined millions of doses of Johnson & Johnson’s COVID-19 vaccine, new information indicates the Maryland-based company sought to hide the deficiencies from federal regulators, all while touting its manufacturing capabilities, according to a BioSpace article.
Takeda Drops One Hunter Syndrome Therapeutic, Puts Faith in Another
/in Business, Central Nervous System Diseases, Clinical Trial Endpoints, Clinical Trials, Collaborations, Hunter Syndrome, Inherited Lysosomal Storage Disorders, Metachromatic Leukodystrophy (MLD), Primary Endpoints, Quarterly results, R&D, Secondary Endpoints, TakedaIn the company’s financial results for 2021 released on May 11, Takeda announced the decision to discontinue the development of TAK-609, a therapeutic for Hunter Syndrome. Additionally, Takeda is collaborating with JCR Pharmaceuticals in another therapeutic attempt for the condition.
New class of cancer drugs down, not out, after Roche trial setback – analysts
/in Advanced non-small-cell lung cancer (NSCLC), Analysts, Blockbusters, Business, Checkpoint proteins, Clinical Trials, Immunotherapies, R&D, Roche, TherapeuticsThe fresh blow to Roche’s hopes in a closely watched class of cancer immunotherapies cast a long shadow across the crowded field on May 11, but the latest setback is not the end of the road for these oncology treatments, analysts say.
Pfizer’s $11.6 billion Biohaven buy could spark more biotech deals
/in Acquisitions, BioNTech, Biotech, Business, Deals, Migraine, Moderna, Pfizer, Potential Blockbusters, R&D, Shares, Therapeutics, Wall Street AnalystsPfizer Inc.’s $11.6 billion deal for migraine specialist Biohaven Pharmaceutical has kindled expectations on Wall Street that the transaction may usher in more buyouts as cash-flush drugmakers look to snap up beaten-down smaller biotechs.